SRSEC Reporting Desk

IFRS & Foreign Private Issuers

What to check in your filing: Review recent comments below against your own disclosure.

26 staff comments from 12 companies. Outcomes: Awaiting / response not in dataset: 18, Agreed to revise: 7, Responded: 1

Clinuvel Pharmaceuticals Ltd (CUVL, CLVLF) · 2026-04-23 · · Comment 1 · 2024 (Unaudited and Presented on an IFRS basis), page F-24 Agreed to revise
Staff comment: As your June 30, 2025 annual audited financial statements are prepared in accordance with U.S. GAAP, all interim unaudited financial statements required in the registration statement must also be prepared under U.S. GAAP as required by Item 8.A.5 of Form 20-F. Note that while foreign private issuers are allowed to initially include more current published information, that published data accommodation does not waive the underlying requirement for consistent accounting standards in a registration statement. Please revise to disclose the following: • Revise to replace your current December 31, 2025 interim unaudited financial statement prepared under IFRS with financial statements prepared… letter →
Company response: In response to the Staff’s comments, we have revised our disclosures beginning on page F-24 of the Registration Statement to replace our current December 31, 2025 interim unaudited financial statement prepared under IFRS with financial statements prepared under U.S. GAAP and also revised other areas of the Registration Statement impacted by the change, including our capitalization table and Item 5. Operating and financial review and prospects. We appreciate the assistance the Staff has provided with its comments. response letter →
IFRS & Foreign Private IssuersCapitalization, Equity & Escrow
Clinuvel Pharmaceuticals Ltd (CUVL, CLVLF) · 2026-04-07 · · Comment 2 · Research and Development, page 35 Awaiting / response not in dataset
Staff comment: We note your revisions in response to prior comment 2, which we reissue in part. Please further revise your discussion related to your announced expansion of the VALLAURIX RD&I Centre to address the following: • Discuss and quantify the support that you are to receive under the five-year investment plan. Disclose whether you are receiving grants, loans and/or other forms of support. Also, discuss your material obligations under the contract as well as the term and termination provisions. • With reference to Items 4.D of Form 20-F, disclose an estimate of the amount of your planned expenditures for the expansion, including the amount of expenditures already paid. Clarify whether these… letter →
KPIs, Metrics & Earnings CallsIFRS & Foreign Private Issuers
Creative Global Technology Holdings Ltd (CGTL) · 2026-03-30 · Form 20-F for Fiscal Year Ended September 30, 2025 · Comment 1 · General Agreed to revise
Staff comment: Please revise future filings, as applicable, to provide more specific and prominent disclosures about the legal and operational risks associated with China-based companies. For additional guidance, please see the Division of Corporation Finance’s Sample Letter to China-Based Companies issued by the Staff in December 2021 (the "CBI Sample Letter"). To the extent the CBI Sample Letter requests disclosure on the prospectus cover page or in the prospectus summary, please provide such disclosure in a separate section at the beginning of Item 3 of Form 20-F; in addition, please include a discussion of the transfer of cash within the company in Item 5 of Form 20-F. letter →
Company response: to the Staff’s comment, the Company will revise future filings, as applicable, to provide more specific and prominent disclosures about the legal and operational risks associated with China-based companies. To the extent the CBI Sample Letter requests disclosure on the prospectus cover page or in the prospectus summary, the Company will provide such disclosure in a separate section at the beginning of Item 3 of Form 20-F; in addition, the Company will include a discussion of the transfer of cash within the Company in Item 5 of Form 20-F. response letter →
China-Based IssuersFiler Status & Cover PageIFRS & Foreign Private Issuers
Mobile-health Network Solutions (MNDR) · 2026-03-25 · Form 20-F for the Fiscal Year Ended June 30, 2025 Filed October 31, 2025 · Comment 1 · Report of Independent Registered Public Accounting Firm, page F-2 Agreed to revise
Staff comment: Please file in an amended Form 20-F, a report from JWF Assurance PAC that fully complies with AS 3101. That is, they should state they audited your balance sheets as of June 30, 2025 and 2024, and the related consolidated statements of operations and comprehensive income, changes in shareholders’ equity, and cash flows for the years ended June 30, 2025 and 2024. They should express an opinion on the financial position of the company as of the balance sheet dates and the results of its operations and its cash flows for the periods then ended. letter →
Company response: We respectfully advise the Staff that we have filed Amendment No. 1 to include an updated report from JWF Assurance PAC that addresses the above. response letter →
Auditor & Audit ReportIFRS & Foreign Private Issuers
Clinuvel Pharmaceuticals Ltd (CUVL, CLVLF) · 2026-03-19 · · Comment 2 · Item 4. Information on the Company, page 22 Awaiting / response not in dataset
Staff comment: We note that your January 12, 2026 press release announced a significant expansion of your VALLAURIX Research, Development and Innovation (RD&I) Centre in Singapore. With reference to Items 4.D. and 10.C. of Form 20-F, please revise to discuss this project and its impact or advise. letter →
Business Description (Item 101)IFRS & Foreign Private Issuers
Clinuvel Pharmaceuticals Ltd (CUVL, CLVLF) · 2026-03-19 · · Comment 8 · Table of Contents, page F-1 Awaiting / response not in dataset
Staff comment: Please revise the table of contents to your Item 18 financial statements to address the following: • Revise to disclose the December 31, 2025 interim financial statements and notes thereto; and • Please distinguish that your interim financial statements are unaudited and presented on an IFRS basis, as opposed to your annual financial statements that are audited and presented on a U.S. GAAP basis. letter →
IFRS & Foreign Private Issuers
Clinuvel Pharmaceuticals Ltd (CUVL, CLVLF) · 2026-03-19 · · Comment 11 · Interim Condensed Financial Statements, page F-24 Awaiting / response not in dataset
Staff comment: Please revise your December 31, 2025 interim financial statements to include a header for each of the statements and notes that prominently include "IFRS" and "Unaudited" for immediate visibility to distinguish them from the U.S. GAAP annual statements. letter →
IFRS & Foreign Private Issuers
Clinuvel Pharmaceuticals Ltd (CUVL, CLVLF) · 2026-03-19 · · Comment 12 · Notes to the Condensed Financial Statements, page F-28 Awaiting / response not in dataset
Staff comment: Please revise the basis of presentation footnote to include that these statements are prepared according to IFRS as issued by the IASB to qualify for the reconciliation exemption under Instruction 4 of Item 8.A.5 of Form 20-F. letter →
IFRS & Foreign Private Issuers
XChange TEC.INC (XHG) · 2026-03-02 · Form 20-F for Fiscal Year Ended September 30, 2024 Response dated September 26, 2025 Form 20-F for Fiscal Year Ended Sep · Comment 2 · Signatures, page 107 Responded
Staff comment: We note your response to prior comment 13 and that your signatures were included prior to the financials statements. The signatures should appear at the end of the Annual Report on Form 20-F following the included financial statements. Please revise in future filings. letter →
Company response: Updated disclosure has been added on pages 5 and 6 of the Amended Registration Statement to include the related party transaction involving Haoju Artificial Intelligence Technology Co., Ltd., as well as the other related party transactions for the period specified in Item 7 of Form 20-F. response letter →
Exhibits, Certifications & SignaturesIFRS & Foreign Private Issuers
Magnitude International Ltd (MAGH) · 2026-02-23 · Form 20-F for the fiscal year ended April 30, 2025 · Comment 1 · Item 15. Controls and Procedures, page 76 Awaiting / response not in dataset
Staff comment: Please amend your filing to disclose the conclusions of your principal executive and principal financial officers, or persons performing similar functions, regarding the effectiveness of your disclosure controls and procedures as of April 30, 2025. Please refer to Item 15(a) of Form 20-F. letter →
ICFR & Disclosure ControlsIFRS & Foreign Private Issuers
Magnitude International Ltd (MAGH) · 2026-02-23 · Form 20-F for the fiscal year ended April 30, 2025 · Comment 2 · Item 16K. Cybersecurity, page 78 Awaiting / response not in dataset
Staff comment: Please tell us why cybersecurity disclosure is not applicable given that Item 16K applies to annual reports on Form 20-F, or amend your filing to include the applicable cybersecurity disclosures. See Instruction to Item 16K of Form 20-F. letter →
Cybersecurity (Item 1C)IFRS & Foreign Private Issuers
Magnitude International Ltd (MAGH) · 2026-02-23 · Form 20-F for the fiscal year ended April 30, 2025 · Comment 3 · Exhibits Awaiting / response not in dataset
Staff comment: We note the certifications required by Rules 13a-14 and 15d-14 of the Exchange Act have been omitted from your Form 20-F. Please file an amended Form 20-F in its entirety and include the certifications from your principal executive officer and principal financial officer, or persons performing similar functions, as exhibits in accordance with the general instructions and instructions as to exhibits of Form 20-F. letter →
Exhibits, Certifications & SignaturesIFRS & Foreign Private Issuers
Phaos Technology (Cayman) Holdings Ltd (POAS) · 2026-02-19 · (Cayman) Holdings Ltd Form 20-F filed September 18, 2025 · Comment 1 · Statements of Operations, page F-3 Agreed to revise
Staff comment: Please identify for us the business, competitive and economic factors that caused your sales to decline by 91%. Explain the underlying reasons for the reduction in sales orders from your largest customers. This information should also be included under Item 5 of your next Form 20-F. letter →
Company response: We respectfully advise the staff as follows: The Company’s revenue for the years ended April 30, 2025 and 2024 were S$167,707 (approximately US$128,464) and S$1,882,803 (approximately US$1,380,848), respectively, representing a decrease of 91.1%. This reduction in revenue was primarily attributed to a reduction in sales orders from our largest customers due to a change in our business strategy in which we directly interact with our customers. As a result, the Company has expanded its sales channel from selling to our distributors to selling directly to customers, with the price of the products remaining largely unchanged, leading to a decline in revenue where sales to distributors have… response letter →
MD&A: Results & Known TrendsIFRS & Foreign Private Issuers
XChange TEC.INC (XHG) · 2026-02-04 · Amendment No 1. to Registration Statement on Form F-3 Filed October 29, 2025 · Comment 1 · General Awaiting / response not in dataset
Staff comment: We note your response to prior comment 1 to our letter dated September 17, 2025 related to your Annual Report on Form 20-F for the fiscal year ended September 30, 2024. Based on your response it appears that you have sold 25,770,000 ADSs since December 2023, the date when your business changed from "technology-driven long- term apartment rental platform in China" to the "insurance agency and insurance technology business" in the PRC. Please provide us with legal analysis as to why the acquisition of the new insuretech business did not constitute a fundamental change that required you to file a post-effective amendment to the registration statement on Form F- 3, file no. 333-258187, to… letter →
China-Based IssuersBusiness Description (Item 101)IFRS & Foreign Private Issuers
XChange TEC.INC (XHG) · 2026-02-04 · Amendment No 1. to Registration Statement on Form F-3 Filed October 29, 2025 · Comment 2 · Page 2 Awaiting / response not in dataset
Staff comment: We note your responses to prior comments 8 and 11 in our letter dated September 17, 2025 related to your Annual Report on Form 20-F for the fiscal year ended September 30, 2024. We also note that the prior transaction with Haoju Artificial Intelligence Technology Co., Ltd. was a related party transaction. Please revise the registration statement to include this related party transaction, as well as other related party transactions for the period specified in Item 7 of Form 20-F. letter →
Related PartiesIFRS & Foreign Private Issuers
XChange TEC.INC (XHG) · 2026-02-04 · Amendment No 1. to Registration Statement on Form F-3 Filed October 29, 2025 · Comment 3 · transactions for the period specified in Item 7 of Form 20-F. Awaiting / response not in dataset
Staff comment: Please provide us with your analysis explaining why the sale of ownership in your apartment rental business and subsequent acquisition of insuretech business did not require shareholder approval or registration under Rule 145 of the Securities Act. letter →
IFRS & Foreign Private Issuers
Clinuvel Pharmaceuticals Ltd (CUVL, CLVLF) · 2026-01-30 · · Comment 7 · Item 4.B. Business Overview, page 24 Awaiting / response not in dataset
Staff comment: We refer to page F-16, which indicates that nearly all of your revenues derive from product sales in Ireland and the United States, and your disclosure on page 28 that Scenesse for EPP patients accounted for approximately 90% of your sales in FY2025. Accordingly, please revise the Overview section to discuss the concentration of sales in these two jurisdictions. Also, revise your Marketing and Sales section to discuss your operations, as well as the coverage, pricing and reimbursement for Scenesse, in these two jurisdictions. letter →
IFRS & Foreign Private IssuersConcentrations & Receivables
Clinuvel Pharmaceuticals Ltd (CUVL, CLVLF) · 2026-01-30 · · Comment 21 · Manufacturing and Logistics, page 32 Awaiting / response not in dataset
Staff comment: Please revise to discuss the availability of raw materials, including a description of whether prices of principal raw materials are volatile. Refer to Item 4.B.4 of Form 20-F. letter →
Business Description (Item 101)IFRS & Foreign Private Issuers
Kandal M Venture Ltd (FMFC) · 2026-01-27 · Form 20-F for the Fiscal Year Ended March 31, 2025 Filed July 30, 2025 · Comment 1 · Item 15. Controls and Procedures, page 77 Agreed to revise
Staff comment: Please amend your filing to explicitly disclose your conclusion regarding the effectiveness of your disclosure controls and procedures as of March 31, 2025. Refer to Item 15(a) of Form 20-F. letter →
Company response: We have revised our disclosure in Item 15 of Part II to the Form 20-F. response letter →
ICFR & Disclosure ControlsIFRS & Foreign Private Issuers
Kandal M Venture Ltd (FMFC) · 2026-01-27 · Form 20-F for the Fiscal Year Ended March 31, 2025 Filed July 30, 2025 · Comment 2 · Item 15(a) of Form 20-F. Agreed to revise
Staff comment: As this is the company’s first annual report, please revise your Form 20-F to include the language required by Instruction 1 of the Instructions to Item 15 of Form 20-F. letter →
Company response: We have revised our disclosure in Item 15 of Part II to the Form 20-F. response letter →
IFRS & Foreign Private Issuers
Macro Bank Inc. (BMA) · 2026-01-15 · Form 20-F for Fiscal Year Ended December 31, 2024 Response Dated September 30, 2025 · Comment 1 · Analysis of the allowance for loan losses and other financing, page 134 Awaiting / response not in dataset
Staff comment: We acknowledge your response to prior comment one. Please revise future filings to provide qualitative information, including a narrative explanation, to explain the reasons for the changes in the expected credit loss (“ECL”) allowance during each period presented. Refer to IFRS 7.35H, .35I and .B8D for guidance. letter →
IFRS & Foreign Private Issuers
RIKU DINING GROUP Ltd · 2025-12-04 · Amendment No. 2 to Registration Statement on Form F-1 Filed November 18, 2025 Amendment No. 1 to Registration Statement · Comment 2 · 1. We note your response to prior comment Awaiting / response not in dataset
Staff comment: Please further revise to provide the information called for by Item 6.B of Form 20-F "for the last full financial year." Consolidated Financial Statements, page F-1 2. Please provide updated audited financial statements, or file as an exhibit to the filing the representations as to why such update is not necessary. Refer to Item 8.A.4 of Form 20-F and Instruction 2 to Item 8.A.4. letter →
Exhibits, Certifications & SignaturesIFRS & Foreign Private Issuers
Lanvin Group Holdings Ltd (LANV, LANWF) · 2025-11-28 · Lanvin Group Holdings Limited Form 20-F Filed on April 30, 2025 · Comment 1 · page 44 Awaiting / response not in dataset
Staff comment: We note you disclose that you qualify as an emerging growth company (“EGC”) and have elected not to opt out of the extended transition period for complying with new or revised accounting standards. Please be advised that the EGC accounting deferral election is not applicable to IFRS filers and revise your disclosures accordingly in future filings. The Company respectfully acknowledges the Staff’s comment. The Company, as an EGC, prepares its financial statements in accordance with International Financial Reporting Standards (“ IFRS ”) as issued by the International Accounting Standards Board and, as an IFRS filer, is not eligible to elect the extended transition period for complying with… letter →
Risk FactorsFiler Status & Cover PageIFRS & Foreign Private Issuers
Lanvin Group Holdings Ltd (LANV, LANWF) · 2025-11-28 · Lanvin Group Holdings Limited Form 20-F Filed on April 30, 2025 · Comment 2 · Reporting, page 131 Awaiting / response not in dataset
Staff comment: Please revise future filings to indicate the framework used by management to evaluate the effectiveness of your internal controls over financial reporting. Refer to Item 308(a)(2) of Regulation S-K. The Company respectfully submits that it will revise the disclosure under Item 15 of its future Annual Reports on Form 20-F to state that management evaluates the effectiveness of the Company’s internal control over financial reporting based on the framework in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. If you have any questions regarding this letter, please contact Howie Farn of Freshfields at… letter →
ICFR & Disclosure ControlsIFRS & Foreign Private Issuers
Dogness (International) Corp (DOGZ) · 2025-11-24 · · Comment 1 · General Awaiting / response not in dataset
Staff comment: Please revise your registration statement to include audited financial statements for your most recent fiscal year. See Item 8.A.4 of Form 20-F. letter →
IFRS & Foreign Private Issuers
HW Electro Co., Ltd. · 2025-11-17 · Post-Effective Amendment No. 1 to Form F-1 Filed September 18, 2025 · Comment 2 · Compensation, page 98 Agreed to revise
Staff comment: Please revise to provide the required compensation information for your fiscal year ended September 30, 2025. Refer to Item 6.B of Form 20-F. Financial Statements Index to Financial Statements, page F-1 3. Pursuant to Item 8.A.4 of Form 20-F, please provide audited financial statements that are no more than twelve months old. Alternatively, to the extent you meet the 15- month criteria outlined in Instruction 2. to Item 8.A.4, file the necessary representations as an exhibit to the registration statement. letter →
Company response: to the Staff’s comments, we revised our disclosure on page 99 of Amendment No. 2 to provide the required compensation information for the fiscal year ended September 30, 2025. Financial Statements Index to Financial Statements, page F-1 3. Pursuant to Item 8.A.4 of Form 20-F, please provide audited financial statements that are no more than twelve months old. Alternatively, to the extent you meet the 15-month criteria outlined in Instruction 2. to Item 8.A.4, file the necessary representations as an exhibit to the registration statement. In response to the Staff’s comments, we filed a request for waiver and representation under Item 8.A.4 of Form 20-F as Exhibit 99.2 to Amendment No. 2. We… response letter →
Exhibits, Certifications & SignaturesIFRS & Foreign Private Issuers
Free weekly digest

New SEC comment letters by topic, notable staff comments, fresh disclosure examples and effective-date reminders. One email a week.

Templates & resources

Listed alphabetically by provider. Listings are not endorsements; no provider pays for placement. All templates & resources